Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sunitinib Malate

FDA-approved product (capsule, oral), marketed as Sunitinib Malate, Sutent.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sunitinib Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Gastrointestinal stromal tumor
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic neuroendocrine tumor
  • Papillary renal cell carcinoma
  • Renal cell adenocarcinoma
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sunitinib Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sunitinib Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients

    NCT01098903 · start 2009-01

    Registered record
    Registry ID
    NCT01098903
    Conditions
    Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    2011-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

    NCT01238055 · start 2008-11

    Registered record
    Registry ID
    NCT01238055
    Conditions
    Advanced Gastric Cancer
    Interventions
    Docetaxel + Sunitinib; Docetaxel only
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2012-10
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Gastric Cancer
    InterventionDocetaxel + Sunitinib; Docetaxel only
    PhasePhase 2
    Registry statusCompleted

  • Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

    NCT00688766 · start 2008-08

    Registered record
    Registry ID
    NCT00688766
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    retaspimycin hydrochloride (IPI-504); placebo; Best supportive care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2009-05
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    Interventionretaspimycin hydrochloride (IPI-504); placebo; Best supportive care
    PhasePhase 3
    Registry statusTerminated

  • Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

    NCT00656669 · start 2008-04

    Registered record
    Registry ID
    NCT00656669
    Conditions
    Breast Cancer
    Interventions
    sunitinib alone; sunitinib plus paclitaxel; doxorubicin and cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-04
    Completion
    2010-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionsunitinib alone; sunitinib plus paclitaxel; doxorubicin and cyclophosphamide
    PhaseNot applicable
    Registry statusCompleted

  • An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

    NCT00618319 · start 2008-02

    Registered record
    Registry ID
    NCT00618319
    Conditions
    GIST
    Interventions
    BIIB021
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    InterventionBIIB021
    PhasePhase 2
    Registry statusCompleted

  • Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

    NCT00631410 · start 2008-01

    Registered record
    Registry ID
    NCT00631410
    Conditions
    Colorectal Neoplasms
    Interventions
    sunitinib + mFOLFOX6; sunitinib + mFOLFOX6
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    Interventionsunitinib + mFOLFOX6; sunitinib + mFOLFOX6
    PhasePhase 1
    Registry statusCompleted

  • Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

    NCT00556049 · start 2007-12

    Registered record
    Registry ID
    NCT00556049
    Conditions
    Renal Cell Carcinoma; Neoplasm Metastases
    Interventions
    Gemcitabine; Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-12
    Completion
    2014-12
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma; Neoplasm Metastases
    InterventionGemcitabine; Sunitinib
    PhasePhase 2
    Registry statusCompleted

  • Clinical Trial of Sutent to Treat Metastatic Melanoma

    NCT00631618 · start 2007-09

    Registered record
    Registry ID
    NCT00631618
    Conditions
    Metastatic Melanoma
    Interventions
    Sutent (sunitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-09
    Completion
    2012-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma
    InterventionSutent (sunitinib)
    PhasePhase 2
    Registry statusCompleted

  • Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

    NCT00694096 · start 2007-09

    Registered record
    Registry ID
    NCT00694096
    Conditions
    Renal Cell Cancer
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2014-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Cancer
    InterventionSunitinib
    PhasePhase 1
    Registry statusCompleted

  • A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

    NCT00491738 · start 2007-08

    Registered record
    Registry ID
    NCT00491738
    Conditions
    Renal Cell Carcinoma
    Interventions
    bevacizumab; sunitinib; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-08
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    Interventionbevacizumab; sunitinib; placebo
    PhasePhase 2
    Registry statusTerminated

  • Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

    NCT00849186 · start 2007-08

    Registered record
    Registry ID
    NCT00849186
    Conditions
    Kidney Cancer
    Interventions
    sunitinib malate; neoadjuvant therapy; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-08
    Completion
    2010-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    Interventionsunitinib malate; neoadjuvant therapy; therapeutic conventional surgery
    PhaseNot applicable
    Registry statusCompleted

  • Sunitinib in Refractory Adrenocortical Carcinoma

    NCT00453895 · start 2007-07

    Registered record
    Registry ID
    NCT00453895
    Conditions
    Adrenocortical Carcinoma
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2012-02
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenocortical Carcinoma
    InterventionSunitinib
    PhasePhase 2
    Registry statusCompleted

  • Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

    NCT00514228 · start 2007-07

    Registered record
    Registry ID
    NCT00514228
    Conditions
    Liver Cancer
    Interventions
    sunitinib malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer
    Interventionsunitinib malate
    PhasePhase 2
    Registry statusCompleted

  • Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

    NCT00392496 · start 2007-02

    Registered record
    Registry ID
    NCT00392496
    Conditions
    Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions
    sunitinib malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2012-01
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
    Interventionsunitinib malate
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

    NCT00444314 · start 2007-02

    Registered record
    Registry ID
    NCT00444314
    Conditions
    Metastatic Renal Cell Carcinoma
    Interventions
    Panzem® NCD; Sunitinib Malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2009-10
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Renal Cell Carcinoma
    InterventionPanzem® NCD; Sunitinib Malate
    PhasePhase 2
    Registry statusCompleted